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Vascular calcification is common in chronic kidney disease,
where cardiovascular mortality remains the leading cause of
death. Patients with kidney disease are often prescribed
vitamin D receptor agonists (VDRAs) that confer a survival
benefit, but the underlying mechanisms remain unclear. Here
we tested two VDRAs in a mouse chronic kidney disease
model where dietary phosphate loading induced aortic medial
calcification. Mice were given intraperitoneal calcitriol or
paricalcitol three times per week for 3 weeks. These
treatments were associated with half of the aortic calcification
compared to no therapy, and there was no difference between
the two agents. In the setting of a high-phosphate diet, serum
parathyroid hormone and calcium levels were not significantly
altered by treatment. VDRA therapy was associated with
increased serum and urine klotho levels, increased
phosphaturia, correction of hyperphosphatemia, and lowering
of serum fibroblast growth factor-23. There was no effect on
elastin remodeling or inflammation; however, the expression
of the anticalcification factor, osteopontin, in aortic medial
cells was increased. Paricalcitol upregulated osteopontin
secretion from mouse vascular smooth muscle cells in culture.
Thus, klotho and osteopontin were upregulated by VDRA
therapy in chronic kidney disease, independent of changes in
serum parathyroid hormone and calcium.
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There is a heavy burden of cardiovascular morbidity and
mortality in patients with chronic kidney disease (CKD).1
Disordered mineral metabolism occurs early in CKD and is
characterized by secondary hyperparathyroidism, elevated
fibroblast growth factor-23 (FGF23) levels, and klotho and
1,25-dihydroxyvitamin D deficiency. Higher 25-hydroxyvita-
min D levels are associated with lower mortality in CKD
patients,2 and observational studies have noted a survival
advantage when dialysis patients are treated with vitamin D
receptor agonists (VDRAs).3,4 VDRAs are currently approved
for the treatment of secondary hyperparathyroidism, but
their association with improved survival is independent of
parathyroid hormone (PTH) levels,5,6 suggesting that other
pleiotropic effects of VDRAs are involved. In contrast to its
beneficial effects, high-dose calcitriol has also been associated
with hypercalcemia, and VDRAs were associated with
vascular calcification (VC) in some animal models.7,8
In vitro data are also conflicting; calcitriol has been shown
to increase vascular smooth muscle cell (VSMC) calcification
in some studies9,10 but not others.11,12 Paricalcitol (19-nor-
1a,25(OH)2D2) is an analog of calcitriol that causes less
hypercalcemia13 and may have a survival benefit over
calcitriol.14 Data from rodent studies are mixed, but suggest
a beneficial effect of VDRAs, especially paricalcitol, on
VC.7,8,12,15,16 Despite human and experimental data suggest-
ing benefits with VDRA therapy, the underlying mechanisms
remain to be clarified.
Many mechanisms contribute to uremic VC, including
systemic calcium/phosphate imbalances, decreased expres-
sion of calcification inhibitors, VSMC osteogenic differentia-
tion, and elastin remodeling.17 The VSMC phenotype change
is particularly striking and can be triggered by elevated
extracellular phosphate.18–20 Large observational studies have
correlated elevated serum phosphate with increased cardio-
vascular mortality in end-stage kidney disease,21 CKD,22 and
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the general population.23 It is noteworthy that phosphate
loading occurs early in CKD stage 3, as evidenced by
increased serum levels of FGF23, which precedes overt
hyperphosphatemia.24
The outcome of VDRA therapy is difficult to predict
because of the myriad of vasculotropic effects (both anticalcific
and procalcific) downstream of vitamin D receptor activa-
tion.25 This complexity emphasizes the need for in vivo studies
to assess the overall consequence of VDRA therapy on VC. In
the present study, we evaluated calcitriol and paricalcitol in
DBA/2J mice that develop marked arterial medial calcification
(AMC) when subjected to CKD and high-phosphate diet.26,27
We demonstrate that both VDRAs decreased the extent of
VC independently of serum calcium and PTH and identify
underlying beneficial mechanisms that include (1) increased
serum klotho and (2) upregulation of VSMC osteopontin.
RESULTS
VDRA therapy was associated with B50% less AMC and
normalized serum phosphate
CKD was surgically induced using partial renal ablation;
non-CKD (NC) controls were not surgically manipulated.
Mice were randomized to receive VDRA therapy intraperi-
toneal for 3 weeks (see Figure 1 for experimental timeline).
The doses tested were 30 ng/kg calcitriol (C30), 100 ng/kg
paricalcitol (P100), and 300 ng/kg paricalcitol (P300). C30
and P100 reflect doses used in current clinical practice, and
we also tested a higher dose of paricalcitol to look for dosage
effect. Diets used were normal (0.5%) phosphate (NP) and
high (1.5%) phosphate (HP) diets.
The extent of VC was assessed via aortic arch calcium
content in all mice. Aortic calcium content in CKD mice on
high (1.5%) phosphate diet (CKDþHP) mice was 8.5-fold
higher than that in NC control mice on normal (0.5%)
phosphate diet (NCþNP) mice. Consistent with previous
reports,26,27 CKD mice on normal (0.5%) phosphate diet
(CKDþNP) mice did not develop aortic calcification.
CKDþHP mice on calcitriol and paricalcitol developed
significantly less AMC, and there was no statistical difference
between the two VDRAs (Figure 2a). Alizarin Red-S staining
of thoracic aorta sections confirmed that calcification was
restricted to the medial layer (Figure 2b). H&E staining
showed straightening of elastic fibers and no atherosclerotic
lesions at areas of calcification; BM8 staining for macro-
phages confirmed lack of inflammation (data not shown).
Serum parameters for the 11 treatment groups are
summarized in Table 1. At the time of randomization,
average BUN in CKD mice was 35±4.7mg/dl as compared
with 28±4.6mg/dl in NC mice; at termination, the average
BUN in CKD mice (38.7±6.4mg/dl) remained significantly
higher than that in control mice (26.9±5.3mg/dl; Po0.05).
CKDþHP mice developed significant hyperphosphatemia
and markedly elevated FGF23 levels. Serum phosphate was
corrected to normal levels and FGF23 was significantly
lowered with VDRA therapy. In CKDþNP mice, calcitriol
significantly raised serum calcium levels, whereas paricalcitol
did not. There was a nonsignificant trend for higher serum
calcium in the CKDþHP mice treated with VDRAs. PTH
levels were not significantly affected by VDRA therapy in
CKD mice, but VDRA therapy significantly raised PTH levels
in the NC control mice on high (1.5%) phosphate diet
(NCþHP) group. We noted less mortality in the VDRA-
treated CKDþHP groups (19/20 mice per group survived
until termination of the study, vs. 16/20 mice in the
CKDþHP group); however, our study was not designed
for survival analysis.
VDRA effects on AMC were independent of serum PTH levels
To determine whether the development of tertiary hyperpar-
athyroidism might explain the lack of serum PTH lowering
by VDRA therapy, a separate cohort of CKD mice (n¼ 8)
were placed on the HP diet for 18.5 days and then switched
to the NP diet for 3 weeks. The PTH levels in these mice
decreased from 1349±612 to 406±346 pg/ml and were
equivalent to levels in the original CKDþNP group, thus
ruling out tertiary hyperparathyroidism. Alternatively, we
considered that the very high (1.5%) phosphate diet used in
the present studies might have blunted the ability of VDRA
to reduce PTH levels. The influence of dietary phosphate
content was examined using a lower (but still above normal)
0.9% phosphate diet that was previously shown to induce
VC in CKD mice.26 CKD mice fed the 0.9% phosphate diet
and treated with the P300 dose showed lowering of serum
PTH to 184±211 pg/ml (n¼ 5) compared with 608±285 pg/
ml in the untreated group (n¼ 3) (P¼ 0.05). Taken together,
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Figure 1 | Experimental design. Chronic kidney disease (CKD)
was induced by partial renal ablation: the right kidney was
exposed, decapsulated, and electrocauterized (surgery 1),
followed by left total nephrectomy 2 weeks later (surgery 2). Non-
CKD control (NC) or CKD mice were placed on normal (0.5%)
phosphate diet (NP) or high (1.5%) phosphate diet (HP) for
3 weeks. Concurrently, mice were either given no treatment,
30 ng/kg calcitriol (C30), 100 ng/kg paricalcitol (P100), or
300 ng/kg paricalcitol (P300). The vitamin D receptor agonists
(VDRAs) were administered via intraperitoneal (i.p.) injections
three times a week for 3 weeks.
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these data suggest that the 1.5% phosphate diet drove PTH
secretion even in the presence of pharmacological VDRA
doses, allowing us to uncover PTH-independent VDRA
inhibitory effects against VC.
Serum and urine klotho, and tubular phosphate excretion,
were increased in CKDþHP mice treated with VDRA
Fractional excretion of phosphate (FEphos) was significantly
higher in VDRA-treated CKDþHP mice, compared with
NCþNP and CKDþHP mice (Figure 3a). Furthermore,
24-h phosphate excretion mirrored the changes in FEphos
(Figure 3b). As PTH levels were not significantly changed by
VDRA therapy and could not account for the increased
tubular phosphate excretion and correction of hyperphos-
phatemia, the FGF23/klotho axis was examined. FGF23 levels
in CKDþHP mice were B5-fold higher than that in
NCþNP mice, and were significantly lowered by VDRA
therapy (Table 1). This FGF23 drop was likely in response to
normalization of serum phosphate levels, as FGF23 levels
were highly correlated with serum phosphate levels in this
study (R¼ 0.58; Po0.001).
Serum levels of klotho, a cofactor for FGF23, were then
examined using immunoprecipitation–immunoblot. Figure
3c and d demonstrates that serum klotho levels were
depressed in CKD. In striking contrast to serum FGF23
levels, calcitriol and paricalcitol both markedly increased
serum klotho in CKDþHP mice (130 kDa band), and these
levels were significantly higher even when compared with NC
controls. Interestingly, coexistence of CKD and phosphate
loading was required for VDRA upregulation of serum
klotho; VDRA therapy per se did not significantly increase
klotho levels in NCþHP or CKDþNP mice (Figure 3d).
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Figure 2 |Chronic kidney disease (CKD) mice on high (1.5%) phosphate diet (CKDþHP) developed vascular calcification that was
significantly decreased by vitamin D receptor agonist (VDRA) therapy. (a) Aortic arch calcium content expressed as mg calcium
normalized to mg dry weight (mean±s.e.m.). *Po0.01 and **Po0.001 compared with the CKDþHP group. Calcification was not different
between the NCþNP (non-CKD control mice on normal (0.5%) phosphate diet), NCþHP (non-CKD control mice on high (1.5%) phosphate
diet), and CKDþNP (CKD mice on normal (0.5%) phosphate diet) subgroups (P¼ 1 for all post-hoc Tukey analyses). Aortic calcium content
was analyzed from all mice in the study (refer to Table 1 for n per group). (b) Thoracic aorta with Alizarin Red-S stain showing marked medial
calcification in the CKDþHP animal (ii) compared with the NCþNP animal (i), and significantly less calcification in an animal treated
with paricalcitol (CKDþHPþ P300, iii). Bar¼ 150mm; original magnification  10. C30, calcitriol 30 ng/kg; P100, 100 ng/kg paricalcitol; P300,
300 ng/kg paricalcitol.
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In addition, immunoblot detected a trend for increased urine
klotho in VDRA-treated CKDþHP mice compared with
untreated CKDþHP animals (Supplementary Figure S1
online). Urinary klotho concentrations did not correlate with
proteinuria; moreover, average proteinuria was the same in
the control and CKD groups (4.4mg/day).
Elevated serum and urine klotho were not explained by
increased renal or parathyroid gland klotho protein levels
following VDRA treatment
In an attempt to identify the source of klotho upregulation by
VDRAs, we first examined the kidney (the major site of
klotho synthesis under healthy conditions28,29). Immunoblot
of kidney lysates is shown in Figure 4a, with the
corresponding densitometric analysis graphed in Figure 4b.
Klotho protein levels were depressed with high-phosphate
feeding alone (NCþHP mice), consistent with a previous
report whereby high-phosphate feeding was associated with
decreased klotho expression and ectopic calcifications in the
kidneys of healthy mice.30 Klotho protein levels were low in
CKD mice (decreased by 30–45 compared with NCþNP
mice) and remained low following VDRA therapy, which was
also evident on kidney immunostaining (Figure 4c).
Quantitative RT-PCR showed an B50% decrease in kidney
klotho mRNA levels in CKD mice regardless of VDRA
treatment (data not shown).
Klotho expression in parathyroid glands was next
examined by immunostaining of neck tissues that had been
dissected out en bloc (Supplementary Figure S2A online).
Analysis of the fractional area with positive staining showed
equivalent parathyroid gland klotho expression in VDRA-
treated versus untreated CKDþHP mice (Supplementary
Figure S2B online). To determine whether the degree of
parathyroid gland hyperplasia might contribute to increased
serum klotho, serial sectioning and three-dimensional
reconstruction were performed.31 We found no difference
in parathyroid gland volumes following VDRA treatment
(Supplementary Figure S2C and D online). Thus, elevated
serum klotho levels could not be explained by parathyroid
hyperplasia in response to VDRA treatment.
Similarly, there was no klotho upregulation in other
tissues surveyed. Klotho expression in human aortas was
recently reported,32 but klotho was not detected in aortas
from healthy or CKD mice by RNA or protein analyses
(Supplementary Figure S3A and B online). Finally, we
examined archival tissue from CKD mice that had been
placed on 0.9% phosphate diet and treated with VDRA. No
upregulation of klotho expression was observed by immuno-
blot of brain, heart, lung, and liver lysates (Supplementary
Figure S3C online), suggesting that increased steady-state
expression in these tissues does not contribute to elevated
serum klotho in VDRA-treated mice. The current data
Table 1 | Serum parameters in the various treatment groups
Treatment group n BUN (mg/dl) Ca (mg/dl) P (mg/dl) PTH (pg/ml) FGF23 (pg/ml) OPN (ng/ml)
Non-CKD groups
NC+NP 9 22±6a 9.9±0.9 9.5±2.2 249±24 203±98 173±41
NC+HP 10 29±5a 9.9±0.6 8.3±0.8 681±173b 473±147c 495±93
NC+HP+C30 10 26±3a 8.9±0.6 10.3±1.3 1699±154b ND 435±119
NC+HP+P300 9 30±4a 9.3±0.6 9.6±1.6 1253±214b ND 441±120
CKD groups
CKD+NP 10 40±8 10±1.5 10.3±1.1 451±81 229±108 185±84
CKD+NP+C30 10 34±5 11.9±1.4d 9.8±0.8 726±188 ND 367±79
CKD+NP+P300 10 45±5 10.1±0.6 10.6±1 457±145 ND 219±64
CKD+HP 16 41±6 9.1±1.6 12.2±1.4 1822±168e 1176±368 746±196
CKD+HP+C30 19 36±5 10.4±0.6 9.1±0.7f 1728±127e 386±168g 610±108
CKD+HP+P100 19 34±3 10.2±0.8 8.3±1.2f 1684±262e ND 359±67h
CKD+HP+P300 19 40±5 9.8±0.8 9±0.7f 1701±113e 336±124g 436±93h
Abbreviations: BUN, blood urea nitrogen; Ca, calcium; C30, calcitriol 30 ng/kg; CKD, chronic kidney disease; FGF23, fibroblast growth factor 23; HP, high (1.5%) phosphate;
n, number of mice in each treatment group; ND, not determined due to insufficient serum; NP, normal (0.5%) phosphate; OPN, osteopontin; P, phosphate; P100, paricalcitol
100 ng/kg; P300, paricalcitol 300 ng/kg; PTH, parathyroid hormone.
Non-CKD control (NC) or CKD mice were placed on normal or high phosphate diet for 3 weeks, and given no treatment, C30, P100 or P300. Each drug was given i.p. three
times a week. All parameters were measured at time of termination except for PTH, which was measured within 24 h following the penultimate VDRA injection. For BUN and
OPN, n=10 per group except for NC+NP and NC+HP+P300 groups where n=9. For serum Ca, n=8 per group except for NC+NP, NC+HP, NC+HP+C30, CKD+NP+C30 and
CKD+NP+P300 groups where n=5. For serum P, n=8 per group; for intact PTH, n=6 per group. For FGF23, n=9 except for NC+NP group where n=8. Data are mean±s.d.
aThe non-CKD control groups had significantly lower BUN compared with the CKD+HP group (Po0.001).
bPTH levels were significantly higher when control mice were placed on the high phosphate diet (P=0.001 compared with NC+NP group); there was a further significant rise in
PTH with C30 and P300 treatment (Po0.001 compared with NC+HP group).
cFGF23 levels were significantly increased in high phosphate-fed control mice (Po0.05 compared with NC+NP group).
dCalcitriol significantly raised serum calcium in normal phosphate-fed CKD mice (Po0.05 vs. CKD+NP group). Although there was a trend for increased serum calcium in the
high phosphate-fed CKD mice treated with calcitriol and paricalcitol, the differences were not statistically significant compared with the CKD+HP group.
ePTH levels in high phosphate-fed CKD mice were not significantly affected by VDRA therapy (P-value was not significant compared with CKD+HP group). Similarly, PTH levels
were not significantly different among the CKD+NP groups.
fCalcitriol and paricalcitol lowered serum phosphate in CKD, high phosphate-fed mice (Po0.001 vs. CKD+HP group).
gFGF23 levels were decreased with VDRA therapy (Po0.001 compared with CKD+HP group).
hOPN levels were significantly lower in paricalcitol-treated groups (Po0.001 vs. CKD+HP group). OPN was also decreased in the CKD+HP+C30 group but P-value was not
significant.
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cannot rule out simultaneous increased expression and
shedding as a mechanism of increasing circulating klotho.
VDRA therapy increased VSMC osteopontin (OPN) expression
in vivo and in vitro
In contrast to serum OPN, which decreased in parallel with
decreased VC (Table 1), aorta immunostaining showed
increased VSMC cytoplasmic expression of OPN in the
VDRA-treated CKDþHP mice (Figure 5a and b). Consistent
with previous findings,26 no OPN staining was observed in
aortas from NC mice (data not shown). As serum klotho was
elevated in VDRA-treated CKDþHP mice, the question was
raised whether OPN upregulation was mediated by VDRA or
by klotho. This was tested in vitro by treating mouse VSMCs
with 2 ng/ml klotho (with/without FGF23) or 50 nmol/l
paricalcitol. Paricalcitol significantly increased OPN levels in
the conditioned media after 48 h, whereas klotho with/
without FGF23 had no significant effect (Figure 5c). OPN
mRNA levels were unchanged (data not shown). We further
evaluated other major regulators of VSMC calcification
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Figure 3 |Renal phosphate excretion and serum klotho were increased by vitamin D receptor agonist (VDRA) treated. (a) Correction
of hyperphosphatemia correlated with increased fractional excretion of phosphate in VDRA–treated CKDþHP animals (fractional excretion
of phosphate (FEphos) calculated from 24-h urine collections expressed as mean percentage ±s.e.m., n¼ 6 for the NCþNP and NCþHP
groups, n¼ 4 for the CKDþHP group, n¼ 5 for the CKDþHPþC30 and CKDþHPþ P300 groups. (b) Total urinary phosphate from 24-h
urine collections was significantly increased in CKDþHP animals compared with the NCþNP group. There was a trend for increased
total phosphate excretion in VDRA-treated CKDþHP mice (P¼ 0.06 and P¼ 0.9 for the CKDþHPþC30 and CKDþHPþ P300 groups,
respectively, compared with CKDþHP animals). (c) Representative blot of serum klotho protein in individual mice from select groups
(upper panel, 130 kDa band). The same blot was stripped and reprobed for immunoglobulin G heavy chain (IgG-HC) as loading control
(lower panel). (d) Serum klotho levels were decreased in CKD, and were increased by VDRA therapy in high phosphate–fed CKD mice to
levels that were significantly higher than that in control mice. VDRAs did not significantly raise serum klotho in the NCþHP and CKDþNP
groups (post-hoc Tukey P-values shown on chart). Levels expressed as arbitrary units normalized to IgG-HC using densitometric analyses
(mean±s.e.m.); n¼ 5 for the NCþNP group, n¼ 6 for the NCþHP, CKDþNP and CKDþHP groups, n¼ 3 in the remaining groups.
*Po0.01 and **Po0.001 compared with the CKDþHP group, and #Po0.05 and ##Po0.001 compared with the NCþNP group.
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including matrix gla protein and the sodium-phosphate
cotransporters PiT-1 and PiT-2, and VDRA therapy did not
change the expression of any of these genes (Supplementary
Figure S4 online).
VDRA therapy did not affect elastin remodeling in CKD mice
Elastin degradation is prominent in our mouse CKD model,
irrespective of dietary phosphate, and precedes overt AMC.27
In end-stage kidney disease, elastin breakdown has been
reported alongside the upregulation of matrix metallopro-
teinase-2,33 and vitamin D deficiency has been associated
with higher circulating concentrations of matrix metallopro-
teinase-9.34 Examination of elastin integrity by eosin
fluorescence showed prominent elastin degradation in the
aortas from all CKD groups (30–50 lamellae breaks per cross-
sectional area vs. four lamellae breaks in the NCþNP
group). VDRA treatment did not decrease the extent of
elastin breaks. There was also no significant difference
between CKD groups in terms of aortic arch desmosine
content (data not shown), indicating no difference in the
amount of functional elastin. Finally, immunostaining
showed equivalent levels of elastolytic matrix metalloprotei-
nase-2 across CKD groups (data not shown). Taken together,
these data suggest that the improvement in AMC following
VDRA treatment was not due to changes in elastin
remodeling.
DISCUSSION
We describe a mouse CKD model that, when challenged with
a high-phosphate diet, develops robust AMC in conjunction
with metabolic derangements that include hyperphosphate-
mia, elevated serum PTH, FGF23, and OPN, and klotho
deficiency. VDRA therapy for 3 weeks with either calcitriol or
paricalcitol resulted in significantly less aortic calcification,
and this effect was independent of changes in serum PTH
and calcium levels. The lower extent of AMC was associated
with elevated serum klotho levels (significantly higher than
that in NC controls), increased phosphaturia, and normal-
ized serum phosphate and FGF23 levels. In addition, OPN
expression in aortic VSMCs was increased by VDRA treat-
ment in vivo and in vitro, in contrast to circulating OPN
levels that decreased in conjunction with reduced VC.
High doses of VDRAs stimulate VC, often in association
with hypercalcemia.12,15,16,35 As in our current study, Mathew
et al.15 noted a protective effect of both calcitriol and
paricalcitol against VC when they used lower (more
physiological) dosages. Other groups have reported differ-
ential stimulation of VC by calcitriol but not by paricalcitol
in CKD rats,12,16 but their experimental protocols differed
in two major aspects: (1) the CKD animals did not develop
VC, and therefore the studies were not capable of detecting
beneficial anticalcification effects, and (2) the degree of
experimental CKD was more severe.
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Figure 4 |Vitamin D receptor agonist (VDRA) treatment did not increase kidney klotho levels. (a) Representative western blot showing
klotho protein (130-kDa band) from whole-kidney lysates (upper panel). The same blot was stripped and reprobed for beta-actin as loading
control (lower panel). (b) Klotho protein in the kidney was significantly decreased by high-phosphate diet (in both control and CKD mice,
##Po0.001 compared with the NCþNP non-CKD group). VDRA treatment did not increase the expression of kidney klotho in CKD
mice. Levels expressed as arbitrary units normalized to beta-actin using densitometric analyses (mean±s.e.m., n¼ 3 for all groups).
(c) Decreased klotho immunostaining in kidneys from NCþHP and CKD mice; (i) NCþNP animal, (ii) NCþHP animal, (iii) CKDþHP animal,
and (iv) CKDþHPþ P300 animal. Bar¼ 50 mm; original magnification  20.
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Although VDRA therapy was associated with a slight
lowering of PTH and a trend for increased serum calcium,
these changes were not significant (Table 1). Our data suggest
that the high dietary phosphate content (1.5%) used in the
present study to achieve more rapid onset of AMC in mice
with mild CKD, compared with the 0.9% phosphate12,26,36
and 1.2% phosphate8,16,37 diets used for longer time periods
in previous studies, drove PTH secretion despite VDRA
supplementation. Indeed, CKD mice on a 0.9% phosphate
diet showed the expected lowering of PTH levels when
treated with VDRA. Dietary phosphate influence was also
evident in the NCþHP group, in which VDRA therapy was
associated with increased PTH levels. A possible explanation
is that VDRAs increased intestinal phosphate uptake, leading
to the induction of PTH secretion as a mechanism to
maintain phosphate homeostasis. The increased 24-h total
urinary phosphate in VDRA-treated CKDþHP mice (Figure
3b) is consistent with increased intestinal phosphate uptake,
especially with calcitriol therapy (P¼ 0.06 between CKDþ
HPþC30 and CKDþHP groups). Overall, our study pro-
vided a unique opportunity to examine the beneficial vascular
effects of VDRAs independent of changes in PTH and calcium.
CKD is a state of klotho deficiency,38,39 and restoration of
circulating klotho is an attractive therapeutic target. There
has been accumulating evidence that soluble klotho can
mediate phosphaturia independent of FGF23. Soluble klotho
in the absence of FGF23 inhibits NaPi cotransporters in
cultured OK cells and in cell-free membrane vesicles.40 In
addition, i.v. administration of klotho leads to decreased
renal expression of NaPi-2a and hypophosphatemia, even in
FGF23-null mice.40 On the other hand, transmembrane
klotho is the coreceptor for renal FGF23 signaling, which
results in phosphaturia via downregulation of NaPi-2a
and -2c in the proximal tubule.41 The ectodomain of klotho
has been shown to bind to exogenously expressed FGF
receptors (FGFRs), suggesting that soluble klotho may be
able to mediate the formation of the FGF23–FGFR–klotho
complex.42,43 The potential role of soluble klotho in FGF23
signaling in vivo remains unknown at this time, but appears
to be a less plausible mechanism for phosphaturia, as in vitro
assays have shown that the affinity of FGFRs for the klotho
ectodomain is log-fold lower than their affinity for full-length
transmembrane klotho.42
Hyperphosphatemia can perpetuate VC via several path-
ways,44 and correction of this metabolic derangement has
been shown to impede the development of VC in clinical
trials.45,46 Indeed, transgenic mice that overexpress klotho,
when subjected to CKD, showed increased phosphaturia and
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Figure 5 | (a) Arterial medial osteopontin (OPN) levels were increased by vitamin D receptor agonist (VDRA) treatment. (i) OPN expression
was low but detectable in the aortic media of chronic kidney disease (CKD) mice fed a high (1.5%) phosphate diet (CKDþHP). VDRA
treatment increased smooth muscle cell expression of OPN in the aortic media in the (ii) CKDþHPþC30, and (iii) the CKDþHPþ P300
animal. Arrows point to aortic medial cells expressing OPN. Bar¼ 30 mm; original magnification  40. (b) Quantification of OPN
immunostaining showed no OPN expression in aortas from non-CKD controls, weak staining in high phosphate–fed CKD mice, and
increased levels in VDRA-treated CKD mice (mean±s.e.m., n¼ 3 for all except CKDþHPþparicalcitol, n¼ 5, where P100 and P300 samples
were grouped). (c) Treatment of cultured vascular smooth muscle cells (VSMCs) with 50 nmol/l paricalcitol increased OPN levels in the
media (significantly higher levels by enzyme-linked immunosorbent assay (ELISA) at 48 h compared with time zero, **Po0.001). Klotho
(KL, 2 ng/ml) with/without fibroblast growth factor-23 (FGF23; 2 ng/ml) did not upregulate OPN secretion. Three wells were sampled
per time point, per treatment group; data are mean±s.e.m. EtOH, ethanol control; P50, paricalcitol 50 nmol/l.
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less VC.39 Klotho was also recently shown to have direct
anticalcification effects at the vascular wall, via inhibition of
sodium-dependent phosphate uptake and VSMC osteoblastic
transformation.39
The VDRA-associated increased serum klotho was modu-
lated by phosphate excess (Figure 3d). A striking and
significant increase in serum klotho was evident only in the
setting of both CKD and dietary phosphate loading.
Interestingly, a phosphate modulatory effect was previously
described with respect to vitamin D effects on gene
expression in cultured human VSMCs.47
Serum klotho is thought to arise from shedding of
membrane-bound klotho from tissues in which it is normally
expressed, and the major site of klotho synthesis is the
kidney.28,29 Calcitriol upregulates klotho in the kidneys of
healthy mice,48 and functional vitamin D–responsive ele-
ments have been located upstream of both the human and
mouse klotho genes.49 VDRAs have also been shown to
upregulate klotho in cultured human and mouse kidney–de-
rived cell lines.50 Thus, it was surprising that our study found
persistently low klotho mRNA and protein levels from the
remnant kidneys of VDRA-treated CKD mice (Figure 4),
suggesting that the kidney was not the source of serum
klotho. Furthermore, although klotho was easily detected in
parathyroid glands by immunostaining, no difference was
detected in CKDþHP mice following VDRA treatment
(Supplementary Figure S2 online). We have not ruled out
inhibition of klotho degradation, nor the possibility that
accelerated shedding of klotho into serum and urine
accounted for the increased levels. Recent studies have
identified the proteases involved in klotho shedding,51,52
although the in vivo significance of the various shed/secreted
isoforms remains unknown. Additional studies are needed to
determine the mechanisms underlying increased klotho in
the setting of CKD and VDRA therapy.
Serum FGF23 levels decreased significantly in the VDRA-
treated CKDþHP mice, and it is likely that production of
FGF23 was downregulated in parallel with correction of
hyperphosphatemia. FGF23 strongly correlated with serum
phosphate levels in the current studies (R¼ 0.58; Po0.001).
Although VDRAs have been shown to markedly increase
FGF23 expression from bone in healthy53 and CKD mice,54
studies in vitamin D receptor–null (VDR/) mice demon-
strated that phosphate can upregulate FGF23 expression
independent of vitamin D.55 Lowering of FGF23 may confer
cardiovascular benefits, as FGF23 has been shown to induce
left ventricular hypertrophy independent of klotho.56 Inter-
estingly, heterogeneity in the response of FGF23 levels to
calcitriol treatment was recently reported in a cohort of CKD
patients; in addition, the study noted a significant correlation
between change in serum phosphate levels and change in
FGF23.57
Upregulation of OPN in aortic VSMCs was the other
major finding of this study. OPN is a potent local inhibitor of
VC58 and has been detected in calcified medial wall deposits
from CKD patients.59 Wu-Wong et al.47 previously reported
that OPN mRNA levels in human coronary VSMCs were
upregulated after treatment with 100 nmol/l paricalcitol for 6
days. We noted upregulation of secreted OPN protein from
mouse VSMCs after 48 h of culture with 50 nmol/l paricalci-
tol. Klotho with/without FGF23 did not upregulate OPN
expression in vitro, suggesting that the increased OPN
expression observed in aortic VSMCs was stimulated by
VDRA treatment and not by klotho. Recently, increased
aortic wall expression of OPN was reported in CKD rats
treated with a supra-therapeutic dose of calcitriol.60 Whether
this upregulation of OPN signifies an overall osteogenic
transformation of VSMCs that, while deterring mineral
deposition, may be maladaptive in terms of vascular wall
contractility remains unclear.
In summary, calcitriol and paricalcitol decreased phos-
phate-induced AMC in CKD mice. We describe novel
mechanisms, including increased serum klotho levels and
upregulation of vascular wall OPN, that could contribute to
the beneficial anticalcification effects of these VDRAs.
Further studies are needed to determine whether these
findings are clinically relevant in terms of cardiovascular end
points.
MATERIALS AND METHODS
Animal studies
Female DBA/2J mice aged 8–10 weeks were purchased from the
Jackson Laboratory (Bar Harbor, ME). Diets included a normal
phosphate (NP) diet containing 0.5% phosphate or a high-
phosphate (HP) diet containing 1.5% phosphate (Dyets, Bethlehem,
PA). The mice underwent partial renal ablation as previously
described,26 whereas NC control mice were not surgically manipu-
lated. HP diet and VDRA treatment (intraperitoneal injections 3 /
week for 3 weeks) were started 2 weeks after renal ablation. Calcitriol
(Sigma–Aldrich, St. Louis, MO) and paricalcitol from Abbott
(Abbott Park, IL) were dissolved in 100% ethanol and diluted in
5% ethanol to desired concentrations. Further details are available in
Supplementary Information online.
Serum chemistries
Blood was drawn from the saphenous vein 4–7 days after surgery 2
to measure blood urea nitrogen (BUN). Interim blood draw was
performed within 24 h after a penultimate VDRA dose to assess PTH
levels. Terminal blood was collected via cardiac puncture following a
2–4-h fast. The following assays were used: the QuantiChromTM Urea
Assay Kit (BioAssay Systems, Hayward, CA) for BUN; the
o-cresolphthalein complexone kit from Teco Diagnostics (Anaheim,
CA) for calcium; the standard bioanalyzer at Phoenix Central
Laboratory (Everett, WA) for phosphate; the mouse FGF23 C-
terminus ELISA kit (Immutopics, San Clemente, CA); the DuoSet
mouse osteopontin ELISA kit (R&D Systems, Minneapolis, MN);
and the mouse intact PTH enzyme-linked immunosorbent assay kits
(ALPCO Diagnostics, Salem, NH and Immutopics). Reference
ranges based on levels in NCþNP mice were as follows: PTH
213.9–274.8 pg/ml and FGF23 76.3–423.5 pg/ml.
Klotho immunoblot
Rat anti-human klotho monoclonal antibody (KM2076) was used
for klotho western blot in urine and immunoprecipitation-enriched
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serum, as well as in tissue lysates. Details are available in
Supplementary Information online.
Quantification of aortic calcium and desmosine
Aortic arch segments were lyophilized and decalcified with 0.6N HCl
at 37 1C for 24h. The calcium content of the supernatant was
determined with the o-cresolphthalein complexone kit (Teco Diag-
nostics). Aortic calcium content was normalized to the dry weight of
the tissue (mg Ca/mg dry weight). Decalcified aortic arch segments
were hydrolyzed in 6N HCl at 100 1C for 24h and the supernatant was
analyzed for desmosine content as previously described.61
Metabolic cage studies
The mice underwent a 24-h urine collection in individual metabolic
cages (Tecniplast, Exton, PA). Urine collections coincided with blood
collections so as to have corresponding serum data. Serum creatinine
was measured using the Quantichrom Creatinine assay kit (BioAssay
Systems). Serum phosphate, urine phosphate, and urine creatinine
levels were measured using an autoanalyzer (Phoenix Central
Laboratory). Fractional excretion of phosphate was calculated using
the following formula: FEphos¼ serum creatinine urine phosphate/
urine creatinine serum phosphate. Urinary protein was determined
using the Pierce Micro BCA Protein Assay Kit (Thermo Scientific,
Rockford, IL).
Histology and immunohistochemistry
The following primary antibodies were used for immunostaining:
klotho (R&D Systems, AF1819), osteopontin (R&D Systems,
AF808), matrix metalloproteinase-2 (R&D Systems, AF1488), and
BM8 (eBioscience, San Diego, CA, 14-4321). Details are available in
Supplementary Information online.
Quantitative RT-PCR
Details are available in Supplementary Information online.
VSMC osteopontin expression
VSMCs from C57BL/6 mice (passage 7) were a gift from Mei Speer.
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Carlsbad, CA) containing antibiotics/antimycotic and
10% FBS. At passage 9, VSMCs were seeded at a density of
2 104 cells/well in six-well plates. At confluence, serum concentra-
tion was lowered to 1% FBS. After an initial 24-h incubation with
1% FBS (time zero), five treatment groups were initiated: (1) vehicle
(EtOH) control because paricalcitol is dissolved in 5% EtOH, (2)
klotho 2 ng/ml, (3) klotho and FGF23 each at 2 ng/ml, (4)
paricalcitol 50 nmol/l, and (5) klothoþ FGF23þ paricalcitol.
Recombinant mouse FGF23 (2629-FG/CF) and klotho (1819-
KL) were purchased from R&D Systems; paricalcitol was provided
by Abbott. OPN in the conditioned media was detected using
the DuoSet mouse osteopontin ELISA kit (R&D Systems) and
normalized to no. of cells/well (averaged from three wells;
Beckman Coulter Z1 Particle Counter, Brea, CA). RNA was
extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA) for
quantitative RT-PCR analysis.
Statistical analysis
SPSS software v16.0 (SPSS, Chicago, IL) was used to compare group
means using one-way ANOVAwith Tukey’s post-hoc analysis. Simple
linear regression was used to obtain correlation coefficients between
two parameters. Significance for all tests was set at Po0.05.
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Figure S2. VDRA treatment did not increase parathyroid klotho or
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